"10.1371_journal.pone.0067052","plos one","2013-06-25T00:00:00Z","Suhrad G Banugaria; Sean N Prater; Trusha T Patel; Stephanie M DeArmey; Christie Milleson; Kathryn B Sheets; Deeksha S Bali; Catherine W Rehder; Julian A J Raiman; Raymond A Wang; Francois Labarthe; Joel Charrow; Paul Harmatz; Pranesh Chakraborty; Amy S Rosenberg; Priya S Kishnani","Division of Medical Genetics, Department of Pediatrics, Duke University Medical Center, Durham, North Carolina, United States of America; Clinical Molecular Diagnostic Laboratories, Duke University Health System, Durham, North Carolina, United States of America; Division of Clinical and Metabolic Genetics, The Hospital for Sick Children, University of Toronto, Toronto, ON, Canada; Children’s Hospital of Orange County, Orange, California, United States of America; Hôpital Clocheville, University Hospital, Tours, France; Department of Pediatrics, Feinberg School of Medicine, Northwestern University, Chicago, Illinois, United States of America; Children's Hospital and Research Center Oakland, Oakland, California, United States of America; Department of Pediatrics, University of Ottawa, Ottawa, Canada; Division of Therapeutic Proteins, Office of Biotechnology Products, Center for Drug Evaluation and Research, United States Food and Drug Administration, Bethesda, Maryland, United States of America","Conceived and designed the experiments: SGB PSK. Performed the experiments: SGB DSB CR JAJR RAW FL JC PH PC PSK. Analyzed the data: SGB SMD CM KBS DSB CR JAJR RAW FL JC PH PC PSK. Wrote the paper: SGB SNP ASR PSK. Helped revise the manuscript: TTP SMD CM KBS DSB CR JAJR RAW FL JC PH PC. Made figures: SGB.","SGB, SNP, TTP, CM, KBS, CWR, FL, PC, and ASR have no financial or proprietary interest in the materials presented herein. SMD has received honoraria from Genzyme. DSB reports receiving research and grant support from Genzyme. JAR has received travel support, speaker fees and his department has received unrestricted educational grants from Genzyme. RYW has a material interest in Biomarin Pharmaceuticals, is a member of the Genzyme/Sanofi Aventis North American Board of Advisors for MPS I, and has received research support from Shire plc. He has received travel and lodging support for attendance to scientific meetings from Genzyme/Sanofi Aventis as well as from Shire plc, and is the local study site principal investigator for the Genzyme/Sanofi Aventis Lumizyme phase III extension trial. JC is a member of the Fabry and Gaucher Disease Registry Advisory Board for Genzyme Corporation. He has received honoraria from Genzyme Corporation. PH has received educational grants, travel support to scientific meetings and speaker's honorarium from Genzyme Corporation. PSK reports receiving research and grant support from Genzyme. PSK also receives honoraria and consulting fees from Genzyme and is a member of the Pompe disease and the Gaucher Disease Registry Advisory Boards. Duke University and the inventors of the method of treatment and precursors of the cell lines used to generate the enzyme (rhGAA) used commercially have received royalties pursuant to the University's policy on inventions, patents, and technology transfer. This potential conflict for Duke University has been resolved through monetization. This does not alter the authors' adherence to all the PLOS ONE policies on sharing data and materials.","2013","06","Suhrad G Banugaria","SGB",16,TRUE,2,10,13,4,TRUE,TRUE,FALSE,0,NA,FALSE
